News · Sleep
Narcolepsy pill that stands in for the brain's missing wake signal kept people awake, in two trials
Type 1 narcolepsy happens when the cells making a wakefulness chemical die off. A drug that mimics that chemical transformed daytime alertness over 12 weeks, with side effects nearly everyone noticed.
- Two randomized, placebo-controlled trials in 273 people aged 16 to 70 with type 1 narcolepsy, over 12 weeks.
- The drug, oveporexton, switches on the receptor normally triggered by orexin, the brain's own wake signal.
- On a test of staying awake in a dim room, people gained 14 to 20 minutes; placebo gained nothing.
- Weekly attacks of sudden muscle weakness fell by roughly 80% to 90% on the drug.
- Needing to urinate more often and trouble sleeping at night affected most people taking it.
Narcolepsy is often played for laughs, the person who nods off mid-sentence. The reality is a condition that makes holding a job, driving or finishing a conversation a daily struggle, and for decades the treatments have worked around its cause rather than at it. Stimulants push wakefulness up; other drugs damp down the sudden attacks. None replaces what is actually missing.
Two phase 3 trials published in the New England Journal of Medicine tested a pill designed to do exactly that, in 273 people with type 1 narcolepsy. Over 12 weeks, the gains in staying awake were large enough to change what a working day looks like.
What goes wrong in type 1 narcolepsy
MedlinePlus Genetics describes narcolepsy as a chronic sleep disorder that disrupts the normal sleep-wake cycle. The type 1 form has a known cause: the loss of a small group of brain cells.
Those cells normally produce chemicals called hypocretins (also known as orexins), and the page notes that hypocretins regulate the daily sleep-wake cycle. Without them the boundary between sleep and waking breaks down, so sleep intrudes into the day and dream-like states intrude into waking. The trial authors list the result: excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hallucinations. Cataplexy is the most distinctive, a sudden loss of muscle strength set off by strong emotion.
How oveporexton works and how the narcolepsy trials ran
The drug does not try to produce orexin. It stands in for it. Oveporexton is an oral orexin receptor 2-selective agonist, meaning a pill that switches on one of the receptors orexin would normally activate, so the brain receives the wake signal even though the cells that send it are gone.
Two trials, called First Light and Radiant Light, randomly assigned people aged 16 to 70 to twice-daily doses or placebo for 12 weeks. The main measure was a laboratory test in which people sit in a quiet, dim room and try to stay awake for up to 40 minutes; healthy people usually manage 20 or more.
What happened to the wake test and to cataplexy
On that test, the change was large. Mean changes in sleep latency ranged from 14.3 to 19.8 minutes with oveporexton, as compared with -0.4 to -0.8 minutes with placebo. People who had been dropping off within minutes were, on average, staying awake for most of the session.
Everyday sleepiness moved too, on a questionnaire asking how likely people are to doze while reading, watching television or sitting in traffic. And the attacks of muscle weakness fell sharply: median percent reductions in the weekly cataplexy rate ranged from 79.0 to 88.8% with oveporexton, against 27.7 to 39.1% on placebo.
The side effects of an orexin pill
Almost everyone noticed something. Adverse events occurred in 86 to 89% of the participants with oveporexton, as compared with 43 to 54% with placebo.
The two most common are consistent with a drug that turns a wake signal up: the most common adverse events were increased urinary frequency and transient insomnia, and each affected most people taking it. Trouble sleeping at night is a real cost for a condition that already fragments sleep, although the trials describe it as temporary. Whether people tolerate these effects for years, not weeks, is what matters next.
What 12 weeks in two trials cannot show
Twelve weeks is short for a condition that lasts a lifetime. Long-term safety, whether the benefit holds, and how the drug interacts with other treatments all need longer study, and the trials were funded by the company developing the drug.
Everyone enrolled had type 1 narcolepsy, the form defined by orexin loss. The drug’s logic depends on that, so there is no reason to assume it would work the same way in type 2 narcolepsy or other causes of daytime sleepiness, and these trials did not test it there.
What this changes for people with narcolepsy
For now, nothing in the medicine cabinet: this is trial evidence, not an approved treatment, and anyone with narcolepsy should stay on what their specialist prescribes.
What it changes is the direction of the field. For the first time, a treatment aimed squarely at the missing signal in type 1 narcolepsy has passed large placebo-controlled trials, with effects on wakefulness big enough to change what a day looks like. If the side effects prove manageable over longer use, that is a different kind of treatment from anything people with the condition have had before.
People also ask
What did the study find?
Mean changes from baseline to week 12 in sleep latency on the Maintenance of Wakefulness Test ranged from 14.3 to 19.8 minutes with oveporexton, compared with -0.4 to -0.8 minutes with placebo. Median reductions in weekly cataplexy rate ranged from 79.0 to 88.8% with oveporexton against 27.7 to 39.1% with placebo. Adverse events occurred in 86 to 89% of participants on oveporexton against 43 to 54% on placebo.
What is orexin?
A chemical made by a small cluster of brain cells that helps keep us awake and holds the sleep-wake cycle steady. It is also called hypocretin. In type 1 narcolepsy those cells are lost.
What is cataplexy?
A sudden loss of muscle strength, usually set off by a strong emotion such as laughing, lasting seconds. It can make a person's knees buckle or their face sag while they stay fully conscious.
How is this different from existing narcolepsy drugs?
Current treatments push wakefulness up or suppress sleep through other brain systems. This is the first class designed to replace the specific signal that type 1 narcolepsy destroys.
What were the side effects?
Needing to urinate more often and short-lived trouble sleeping were the most common, each affecting most people on the drug. Adverse events of any kind were reported by close to nine in ten.
Can people get it?
Not yet, as far as these trials go; they are the evidence regulators will weigh. Anyone with narcolepsy should keep to their current treatment and discuss new options with their specialist. This is general information rather than medical advice.